Karlen S, De Boer M L, Lipscombe R J, Lutz W, Mordvinov V A, Sanderson C J
TVWT Institute for Child Health Research, West Perth, Australia.
Int Rev Immunol. 1998;16(3-4):227-47. doi: 10.3109/08830189809042996.
Interleukin-5 (IL5) is a T cell-derived cytokine involved in the pathogenesis of atopic diseases. It specifically controls the production, the activation and the localization of Eosinophils. The Eosinophils are the major cause of tissue damage resulting in the symptoms of asthma and related allergic disorders. T cells purified from bronchoalveolar lavage and peripheral blood of asthmatics secrete elevated amount of IL5. Therefore IL5 emerges to be an attractive target for the generation of new anti-allergic drugs. Agents which inhibit either the production or the activity of IL5 could be expected to ameliorate the pathological effects of the allergic response. A better understanding of the biology of IL5 and the regulation of its expression is, however, a prerequisite for the development of new therapeutic agents. This review covers the major biological, molecular and structural aspects of IL5 research since the identification of this cytokine ten years ago.
白细胞介素-5（IL5）是一种由T细胞产生的细胞因子，参与特应性疾病的发病机制。它特异性地控制嗜酸性粒细胞的产生、激活和定位。嗜酸性粒细胞是导致哮喘和相关过敏性疾病症状的组织损伤的主要原因。从哮喘患者的支气管肺泡灌洗物和外周血中纯化的T细胞分泌的IL5量升高。因此，IL5成为开发新型抗过敏药物的一个有吸引力的靶点。预计抑制IL5产生或活性的药物可改善过敏反应的病理效应。然而，更好地理解IL5的生物学特性及其表达调控是开发新治疗药物的先决条件。这篇综述涵盖了自十年前发现这种细胞因子以来IL5研究的主要生物学、分子和结构方面。
